GT Biopharma, Inc. (GTBP) vs VistaGen Therapeutics, Inc. (VTGN)

GT Biopharma, Inc. and VistaGen Therapeutics, Inc. are both Biotechnology companies. GT Biopharma, Inc. and VistaGen Therapeutics, Inc. are of similar size ($12.7M and $12.3M). VistaGen Therapeutics, Inc. grew revenue faster over the last twelve months: 287.2% against −76.2%. GT Biopharma, Inc. has the higher net margin (0.00% vs −2,703.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, GT Biopharma, Inc. leads on 8 and VistaGen Therapeutics, Inc. on 8.

Valuation

Metric GTBP VTGN Biotechnology median
P/E n/m n/m 7.88
P/S 178.31 4.64 11.47
P/B 3.00 0.47 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.28 0.74
EV/Sales 96.13 (7.84) 10.73
Earnings yield (2,140.78%) (614.81%) (28.84%)
Free cash flow yield (133.29%) (538.13%) (23.03%)

Profitability

Metric GTBP VTGN Biotechnology median
Gross margin 41.67% 100.00% 65.16%
Operating margin 0.00% (2,785.69%) 0.00%
Net margin 0.00% (2,703.72%) 0.00%
Free cash flow margin 0.00% (2,490.88%) 0.00%
Return on equity 102.03% (166.46%) (57.72%)
Return on assets (176.27%) (129.22%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GTBP VTGN Biotechnology median
Revenue growth (TTM) (76.19%) 287.15% 5.64%
EPS growth (last fiscal year) 3.75% (9.58%) —
Revenue growth, 5-year CAGR 19.67% 3.10% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP VTGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.61 3.07 4.73
Net debt to EBITDA 0.56 0.63 0.96

Dividend

Metric GTBP VTGN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GTBP VTGN Biotechnology median
Market cap 12.32m 12.65m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack